Augsburg University

Idun
Theses and Graduate Projects
2022

In individuals aged 9-26, will increasing provider and parent
education about the human papillomavirus (HPV) vaccine
increase the rate of HPV Vaccination
Jessica Thonack
Augsburg University

Follow this and additional works at: https://idun.augsburg.edu/etd
Part of the Public Health Commons

Recommended Citation
Thonack, Jessica, "In individuals aged 9-26, will increasing provider and parent education about the
human papillomavirus (HPV) vaccine increase the rate of HPV Vaccination" (2022). Theses and Graduate
Projects. 1237.
https://idun.augsburg.edu/etd/1237

This Open Access Thesis is brought to you for free and open access by Idun. It has been accepted for inclusion in
Theses and Graduate Projects by an authorized administrator of Idun. For more information, please contact
bloomber@augsburg.edu.

In individuals aged 9-26, will increasing provider and parent education about the human
papillomavirus (HPV) vaccine, compared to current practice, increase the rate of HPV
vaccination?

By:
Jessica Thonack, PA-S

Masters Advisor:
Eric Van Hecke, MPAS, PA-C, CAQ-EM

Paper Submitted in Partial Fulfillment
of the Requirements for the Degree of
Master of Science in Physician Assistant Studies
Augsburg University

Thonack 2

Table of Contents
Abstract…………………………………………………………………………………………. 3
Introduction………..………………………………………………………………………….. 5-6
Methods…………………………..…………………………………………………………....... 6
Review of the Literature…..……………….………………………………………………… 6-19
Discussion/Analysis….……...……………………………………………………………… 20-23
Conclusions………...………………………………………………………………………. 23-24
References………………………………………………………………………………….. 25-26

Thonack 3

In individuals aged 9-26, will increasing provider and parent education about the HPV vaccine,
compared to current practice, increase the rate of HPV vaccination?

Abstract
Background: HPV is the most common sexually transmitted infection (STI) affecting millions
of individuals in the United States (US). Since the introduction of the HPV vaccine, infections
have declined. Yet, many adolescents remain unvaccinated.1 This review analyses the vital role
of provider and patient education in increasing the rate of HPV vaccination, and what strategies
can be implemented to improve HPV vaccine coverage.
Purpose: The purpose of this review is to describe the factors that affect HPV vaccination
numbers and how to increase HPV vaccination rates. In individuals aged 9-26, will increasing
provider and parent education about the HPV vaccine, compared to current practice, increase the
rate of HPV vaccination?
Methods: Search engines included PubMed, Jamanetwork, and the CDC using the search terms:
human papillomavirus, HPV, HPV vaccination, HPV epidemiology, HPV provider education,
HPV patient education, HPV trends, and increasing HPV vaccination. Inclusion criteria were
studies that were published in 2017 or later, original research, and free full text. Exclusion
criteria were studies that were published before 2017 and systemic reviews.
Conclusions: Increasing both provider and patient knowledge about the HPV vaccine will
increase the vaccination rate. Strategies include HPV continuing education for providers, HPV
health campaigns, and increasing access to Vaccine for Children (VFC) providers. 2,3,4,5,6,7 More
studies are needed to target the lower vaccination rates in non-Hispanic Whites and in
adolescents with mothers with higher education.2
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Introduction
In order to answer the research question, “In individuals aged 9-26, will increasing
provider and parent education about the HPV vaccine, compared to current practice, increase the
rate of HPV vaccination?”, this literature review will first provide a historical review of HPV.
The current literature surrounding HPV will be presented, followed by vaccination trends, and
health care recommendations. Then a comprehensive discussion analyzing the entirety of the
literature will lead to conclusions, including the next steps and potential for future research and
strategies.
HPV is the most common STI in the US with a prevalence of over 40 million, costing the
healthcare system over three-quarters of a billion dollars. There are over 200 types of HPV with
over 40 strains causing several types of cancer. There are multiple risk factors that increase the
chance of contracting the virus and high-risk types can persist for many years. HPV vaccination
is the best prevention. After the implementation of the HPV vaccine in 2006, infections
decreased significantly.1 However, 25% of adolescents remain unvaccinated.2
Lu et al2 reported that HPV vaccinations increased when providers made
recommendations and the parents received education. Researchers also noted many
socioeconomic differences between adolescents who were vaccinated and those who were not.
Sonawane et al3 documented that most parents who refused the vaccine cited they had safety
concerns. This was found to be a result of misinformation being distributed throughout social
media. Sundstrom et al4 also recognized the negative impact of misinformation on social media
and created an online learning environment educating parents about HPV. This increased parent
knowledge and confidence to discuss HPV vaccination within their social networks. Shay et al 5
reported providers who engage in HPV education when parents exhibit hesitancy are more likely
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to agree to vaccination after their concerns are addressed. Warner et al6 and Daniel et al7
identified major HPV vaccination barriers existing in rural areas and in communities that lacked
a VFC provider. Increasing provider education, enrolling more providers in the VFC program,
and implementing health campaigns in these areas, increased HPV vaccination rates
considerably.6,7
Methods
A comprehensive literature review was conducted using PubMed, Jamanetwork, and
CDC using the search terms: human papillomavirus, HPV, vaccination, epidemiology, provider
education, patient education, trends, and increasing vaccination. Inclusion criteria were studies
that were published in 2017 or later, original research, and free full text. Exclusion criteria were
studies that were published before 2017 and systemic reviews. The articles were analyzed and
compared with one another. Limitations and biases were also noted.
Review of Literature
In 2018, an estimated 1 in 5 people in the US had an STI, totaling a prevalence of almost
68 million and an incidence of 26 million. Newly acquired STIs accounted for $16 billion in
direct medical costs. Almost half of these new STIs occur in individuals ages 15-24. Topping
the charts with a prevalence of 42.5 million and an incidence of 13 million, HPV has reigned
supreme as the most common STI. New HPV infections cost the United States healthcare
system $755 million in direct lifetime medical expenses.8
HPV is a small, double-stranded deoxyribonucleic acid that infects cutaneous or mucosal
epithelium. There are over 200 types of HPVs, most of which infect the cutaneous epithelium,
causing common skin warts. There are about 40 types that infect the mucosal epithelium and are
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associated with cancer. HPVs are divided into 2 categories: low-risk HPVs and high-risk HPVs.
Low-risk HPV strains are responsible for cutaneous and anogenital warts, and high-risk HPV
strains are responsible for cervical, vulvar, anal, vaginal, penile, and oropharyngeal cancer. 9 In
addition to warts, low-risk HPVs such as types 6 and 11, can cause benign cervical cell
abnormalities and respiratory papillomas. High-risk HPVs such as types 16 and 18, can cause
benign cervical cell abnormalities as well, in addition to precancerous cells, and anogenital and
oropharyngeal cancers.
Most HPV infections, whether it be low- or high-risk types, are typically cleared by the
host’s immune system within 2 years and do not cause cancer. HPV infection is exceedingly
common and most individuals who are sexually active will contract HPV at some time in their
lives. Low-risk types can be asymptomatic. However, for some persistent high-risk types that
last many years to decades, cancerous cells may develop without treatment. Persistent infection
is the greatest risk factor for eventually developing cervical cancer because almost all cervical
cancers are caused by HPV. Some factors such as immunosuppression, tobacco use, long-term
use of oral contraceptives, and low socioeconomic status are known to increase the chance of
HPV persistence. High-risk types 16 and 18 are responsible for around 70% of all cervical
cancers. Other strains responsible for causing cancer include types 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, and 68, which together cause about 25% of cervical cancers. In some instances of
infection of the mucosal epithelium, individuals may be infected with multiple types of HPV.
There is no required medical management for asymptomatic, low-risk types besides following
for disease progression. High-risk type treatments include cold knife conization, cryotherapy,
loop electrosurgical excision procedure, and thermal ablation.10
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HPV is spread through sexual activity where there is skin-to-skin contact with someone
who is infected. Transmission is usually through penile, vaginal, anal, or oral sex. Penetrative
sex is at the highest risk. Individuals usually contract HPV soon after their first sexual
encounter.1 Infection rates are estimated at around 50% 3 years after initial sexual contact. 11
Autoinoculation may also be possible through hand-to-mouth or hand-to-genital transmission.
However, there is still debate as to whether this is due to the reactivation of latent infection or if
there are alternative modes of transmission.12 Because there are so many new infections reported
each year, it is evident that communicability is high. Having multiple sexual partners or having a
sexual relationship with someone who has had numerous sexual partners is one of the greatest
risks. Having sex at an earlier age or having a history of other STIs are also risk factors. 13
The best way to prevent getting infected with HPV is through vaccination. This protects
the vaccinated individual as well as any of their sexual partners by preventing transmission.
Physical barriers like condoms, merely play a role in the reduction of transmission, but only if
they are used correctly and consistently. Before the introduction of the HPV vaccine in 2006,
there was a prevalence of approximately 79 million HPV infections in the US and an incidence
of 14 million new infections a year. In 10 years after the arrival of the vaccine, HPV infection
numbers dropped dramatically. Females aged 14 to 19 years old saw an 86% decrease, whereas
females aged 20 through 24 saw a 71% decrease.
Cervical cancer screening can prevent most cases of cervical cancer. This is done during
a Papanicolaou test performed by healthcare providers. Cervical cells are collected and placed
on a slide (traditional smear) and/or in liquid media (cytology). The American College of
Obstetrics and Gynecologists (ACOG), U.S. Preventive Services Task Force (USPSTF), and the
American Cancer Society (ACS) do not recommend annual screening for cervical cancer in those
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who are at average risk. ACOG and USPSTF recommend cytology screening every 3 years from
ages 21 to 29 years for average-risk individuals, whereas the ACS does not recommend
screening until age 25 years. From ages 30 to 65 years, screening is recommended every 3 years
with a cytology test, or every 5 years with an HPV test only or with cytology in addition to an
HPV test.1 An HPV test is a specific genotyping analysis for high-risk types 16 and 18. This
increases the sensitivity of detecting high-grade cervical intraepithelial neoplasia.14 It is
important to note that a positive HPV vaccination status does not exclude someone from HPV
screening. This is because the HPV vaccine only covers a limited number of strains. It is
estimated around 15% of cervical cancers are caused by types not prevented by the vaccine. 1
The U.S. Food and Drug Administration (FDA) has approved 3 different types of HPV
vaccines, which only cover a limited number of strains. The first HPV vaccine was introduced in
2006 and prevents infection from high-risk types 16 and 18. Later, a 4-valent vaccine was
created that covers both low-risk types 6 and 11 and high-risk types 16 and 18. Currently in use
in the US, is a 9-valent HPV vaccine (Gardasil 9) that prevents infection from types 6, 11, 16,
18, 31, 33, 45, 52, and 58; protecting individuals from 2 types that cause condyloma acuminata
and 7 types that cause cancers of the anogenital tract and oropharynx.15
HPV vaccination can be given as early as age 9 years for females and males, although it
is routinely recommended for ages 11 to 12 years. Children with a history of sexual abuse can
begin their vaccination initiation at 9 years of age. Vaccination is recommended for ages up to
26 years for catch-up in cases where individuals have not yet been adequately vaccinated. HPV
vaccines have been approved for up to age 45 years where shared decision-making between
provider and patient shall take place to assess risk factors for ages 27-45 years. Beyond the age

Thonack 10

of 26, it is less common to acquire new HPV infections. Risk factors to consider are having new
or multiple sex partners.
Administration of the HPV vaccine is done in either a 2-dose or 3-dose series. This will
depend on certain immunocompromising medical conditions and age upon the first dose. A 2dose schedule is done for those who receive their first dose before their 15th birthday. Then a
second dose can be made anywhere between 6 to 12 months after the initial dose, with no less
than a 5-month interval. If done less than 5 months, a third dose will have to be administered at
least 3 months after the second dose to be effective. A 3-dose series is utilized if the initial dose
is administered on or after their 15th birthday or in individuals who have an immunodeficiency
that will lessen an immune response. The second dose in a 3-dose series is done 1-2 months
after the initial dose, and the third dose is done 6 months after the second dose. Dosing
schedules can be resumed as soon as possible in cases where there have been interruptions in
recommended time frames from the initial dose.1 Recently, there have been studies showing the
efficacy of a single-dose HPV vaccine. In research performed by Basu et al16, a single dose of
the 4-valent vaccine was found to be just as effective at 10 years, compared to a 2-dose and 3does series.16
The goal is to complete the HPV vaccination series before there is any sexual contact
because the vaccine is prophylactic and not therapeutic. The vaccine will have no effect on
already acquired HPV infections, associated lesions, or anogenital warts. For those who have
already had sexual contact, the completion of the series is still recommended up to age 26 years
because the vaccine covers multiple strains. Even though individuals may have been exposed to
one or more HPV types, the vaccine will still offer protection from the remaining strains. The
HPV vaccine is highly effective with an antibody response of over 98% to all covered strains
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upon completion of the series. To improve HPV vaccination rates, providers should administer
them at the same time as other scheduled vaccines. This can be done along with the Tdap and
meningococcal vaccines, which are also recommended for ages 11 to 12 years.1
Lu et al2 evaluated the factors associated with the initiation of the HPV vaccine and the
components related to vaccination status in adolescents aged 13 to 17 years from 2015 to 2020.
Data was collected from the National Immunization Survey-Teen (NIS-Teen) to evaluate trends.
A wider range of ages could not be assessed because the NIS-Teen only evaluates youth aged 13
to 17 years. Independent variables associated with vaccination were evaluated using the
multivariable logistic regression formula.
Researchers found an increase from 56.1% in 2015 to 75.4% in 2020 in vaccination doses
of 1 or more for adolescents, totaling an over 19% increase. Males showed larger increases than
females and narrowed the range between the sexes. In 2020 males were at 73.7% coverage and
females were at 76.8% coverage. Provider recommendation increased numbers to 80.7%
compared to no provider recommendation at 51.7%. For adolescents who were seen for a wellchild visit, coverage was at 80.3% compared to those who did not have a well-child visit at
64.8%. Independent variables linked to an increased rate of vaccination involve a
recommendation by a provider, age 11 to 12-year well-child visit, age 16 to 17 years, having at
least 1 vaccine provider, having visits with at least 2 providers in the past year, Hispanic, nonHispanic Black, Alaskan Native, American Indian, and Medicaid insurance.
The frequency of HPV vaccine provider recommendations increased from 68.4% in 2015
to 81.5% in 2020 for ages 13 to 17 years. Well-child visits for ages 11-12 years increased
slightly from 46.3% to 50.4%. Vaccination among those visits increased from 61.6% to 80.3%.
Completion of vaccine series increased by 19%. Hispanic and non-Hispanic Black vaccine
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coverages were higher at 80.7% and 78.3% compared to non-Hispanic Whites at 71.4%. The
data also shows vaccine numbers were higher among adolescents with mothers who had less than
a high school education compared to those who had mothers with a high school education or
more. Additional research needs to be done to assess this finding. Vaccination rates were also
found to be considerably higher in metropolitan regions compared to rural areas. This inequity is
uncertain but may be due to decreased provider recommendations and less education on HPV
vaccination in rural settings. Independent variables also leading to a higher vaccination level
include having a mother who is divorced, separated, or widowed, and having an income-topoverty ratio of less than 133%.
Despite the significant increase in HPV vaccination rates, about 25% of adolescents aged
13 to 17 years remain unvaccinated. Approaches aimed at increasing these numbers and
decreasing disparities are essential. Studies indicate the greatest impact on raising HPV vaccine
coverage is provider recommendation. Researchers found parents are more likely to agree to
vaccination or change their decision to refuse the vaccine when providers give education and
relay the importance of protection from HPV and its related diseases. Every healthcare visit
should include a review of vaccination history to increase the likelihood of receiving
recommended vaccines. Even with the increase in provider recommendations, other interjecting
factors play a role in vaccine refusal. Disparities between ethnicities may be the result of
programs that increase access to vaccines for adolescents with little to no health insurance, or
providers using recommendations based on their perceived risk factors. From these findings,
more strategies should be geared toward providers who deliver care to non-Hispanic White
adolescents.
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Even though this study states HPV vaccinations have significantly increased, there
remain two limitations to the results. The number of adolescents who responded to the
interviews in 2020 was only 20.7% and the providers who confirmed and supplied additional
data was 45.2%. Also, bias may persist after households with no response or no phone have
been adjusted.2
Sonawane et al3 performed a study assessing the trends in HPV vaccine safety concerns
using data from the NIS-Teen and compared it to the adverse event (AE) reporting from the
Vaccine Adverse Event Reporting System (VAERS). Data evaluated from 2015-2018 found the
top reason for adolescents not getting the HPV vaccine was due to parent safety concerns.
Interestingly, this is in contrast with a decrease in AE reports filed with VAERS.
The HPV vaccine was shown to be safe and effective before FDA approval and was
verified safe by VAERS through multiple studies after licensure. Despite proven safety, views
toward the HPV vaccine have been negatively impacted due to misinformation presented through
social media. VAERS is crucial for informing the public of vaccine safety. So, when an inverse
relationship occurs between increased safety concerns and decreased AE reporting, it is highly
suggestive it is due to public misinformation.
There were 39,364 respondents with an unvaccinated status. The main demographics
associated with these adolescents were non-Hispanic White, male, privately insured, and came
from households over the poverty level. This data supports the findings in the previous study
performed by Lu et al. The main reasons for not receiving the vaccine were “Safety concerns,”
“Not needed or not necessary,” “Not recommended,” “Not sexually active,” and “Lack of
knowledge.” Safety concerns increased by almost 80%, with sizable increases in California,
Mississippi, South Dakota, and Hawaii which saw more than a 200% increase. Reports state that
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California has the most exposure to negative content about the vaccine, which relates directly to
having the most significant increase.3 An increase in vaccine safety concerns has also been
reported in an earlier study analyzing statistics from 2010 to 2016.17 Data from this current
study continues to see this trend. In contrast, AE reporting decreased from 44.7% to 29.4%.
Nonserious AEs, which account for over 95% of all reported AEs, decreased significantly, while
serious AEs stayed steady.
Misinformation exists on many platforms, especially social media. The internet plays a
significant role in why parents have safety concerns because they rely on it to get information
about vaccines. Unfortunately, they find unproven AEs, anti-vaccine content, stories about
unfounded vaccine injuries, conspiracies, and false risks. This deceptive content leads to vaccine
hesitancy and refusal.
In response to gaining trust in the HPV vaccine, as well as others, the CDC has initiated
the Vaccine with Confidence Program in the United States. The American Medical Association
has also stepped in to encourage social media companies to combat vaccine misinformation.
Accurate vaccine education is important and using social media to inform about safety and
effectiveness will prove to be paramount. In addition, provider intervention and education are
also needed to relay credible information about the HPV vaccine to decrease parent safety
concerns.
This study had some limitations. As in the prior study, this analysis utilized the NISTeen, which only accounts for adolescents aged 13-17 years, leaving out other vaccine-eligible
ages. It cannot be assumed this data applies to other age groups. The utilization of VAERS is
limited by spontaneous reports, which can lack essential information about preexisting
conditions, other vaccines administered, and current medication. AE reports can also be subject
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to bias because non-serious AEs may be underreported. Lastly, two different sources were
utilized to assess safety concerns and AE reporting, thus they are not currently linked. 3
In accordance with Sonawane et al3, Sundstrom et al4 also found social media to have a
tremendous impact on the spread of HPV vaccine misinformation. Exposure to harmful material
about the vaccine led parents to question its safety and effectiveness, which also led to more
negative posts. Interestingly, those in support of or neutral on the subject matter were more
likely not to express their opinion on social media.
Mothers play a significant role in making medical decisions for their children, in addition
to being highly active in social media. Despite having an overall high degree of trust in
providers, social media and networks remain the most influential source. Sundstrom et al4 set
out to produce a technology-based platform aimed at educating moms and creating social media
champions to combat the onslaught of HPV vaccine misinformation.
These mothers received HPV vaccine education through online training for 3 months,
which consisted of bi-weekly emails, 2 webinars, and a private Facebook group. The goal was
not only to educate mothers, but also to provide them with easy and shareable materials, and give
them the confidence to engage in conversations through their social networks and on social
media about the importance of the HPV vaccination.
As a result, the participants reported a significant increase in knowledge about HPV and
the vaccine. Mothers noted not knowing beforehand how males were susceptible or that HPV
can also lead to head and neck cancers. They also found they were more confident to discuss
HPV vaccination within their social networks and on social media. This study supports the need
for online HPV education and shareable, easily-understood material to combat misinformation.
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This is especially important for parents who would not normally be so vocal about the choice to
vaccinate their children.
The generalizability of this study was limited by the small sample size and similar
demographics of the participants. While future studies can include fathers, the greatest impact
will be seen from pro-vaccine mothers due to their higher presence on social media outlets. In
the wake of the pandemic, this model can help fight the anti-vaccine movement.4
Shay et al5 recorded 43 well-child visits with pediatricians and their patients, all of which
included the HPV vaccine recommendation. The purpose of their study was to evaluate the
different ways parents expressed hesitancy to this recommendation and how pediatricians
responded. Researchers found most parents who are undecided respond with hesitancy, which
was most likely conveyed with a concern or question. The remaining responses were assertive.
In visits where pediatricians continued engaging in conversation and expressing the importance
of the vaccine and answering any concerns or questions, most parents agreed to vaccination.
However, in cases where the pediatrician did not engage in patient education with a hesitant
parent, none of them agreed to vaccinate their child. From these findings, it can be concluded
that most vaccine-hesitant parents can be amenable to their child receiving the HPV vaccine if
providers continue the conversation with rational patient education. The time spent discussing
the HPV vaccine was estimated to only last about 2-3 minutes between providers and
parents/patients.
This study has a few limitations. Participants could not be blinded because of the
presence of an audio recorder, which may have modified how pediatricians and parents
correspond with one another. Non-verbal evaluation of hesitancy was not assessed.
Generalizability is limited because the study does not evaluate parents who have already decided
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to vaccinate or not. Also, participants were mostly Hispanic or African American and came
from low-income households.5 As stated earlier, in the study done by Lu et al2, vaccination status
was higher among low-income Hispanic and non-Hispanic Blacks. In the study done by
Sonawane et al3, unvaccinated status was highest among middle- to high-income non-Hispanic
Whites. I think it would be beneficial to assess types of hesitancy in other racial groups that
have lower vaccination numbers.5
Warner et al6 surveyed providers in Utah about their knowledge of and perceived barriers
to HPV vaccination. Researchers chose Utah because of its very low vaccination rate and a
previous study indicating providers in this state had less knowledge about HPV. They found that
provider specialty and practice type was associated with less knowledge of the HPV vaccination.
Furthermore, providers aged 30-39 and equal to or more than 50 years, had less knowledge than
middle-aged providers aged 40-49 years.
The lack of knowledge in younger providers during this time may be due to receiving
clinical training before the approval of the HPV vaccine and having less continuing education.
Providers who were not enrolled in the federally-funded VFC program and those who did not
routinely give vaccinations had lower knowledge. Providers in rural areas had less knowledge
than providers in urban areas. The goal here would be to deliver targeted continuing education
regarding the HPV vaccine to increase provider knowledge and thus increase their
recommendation.
The overall qualitative assessment of providers’ perception of barriers to HPV
vaccination is parent education and misinformation. Providers communicated the need for
simple and effective educational materials which can be easily shared with parents.
Additionally, they agreed that public health campaigns geared toward local numbers on HPV
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prevalence and expressing vaccination as cancer prevention are effective strategies to help
increase vaccinations. Interestingly, researchers found some providers had negative views about
the vaccine and were resistant to giving a recommendation. Providers also expressed they were
reluctant to discuss sexual health at this age and lacked the time necessary to explain the benefits
of the HPV vaccine.6 As reported in the previous study mentioned, by Shay et al5, conversations
about HPV only lasted about 2-3 minutes, and parents were more likely to agree to vaccination if
their provider gave a recommendation and provided parent-patient education. Warner et al6
concluded provider knowledge most likely has a direct relationship to parental knowledge, in
that low-knowledge providers are less likely to discuss the HPV vaccine, contributing to the low
knowledge of parents.
There are a few limitations to this study. This study was only done in the state of Utah
which limits the external validity. However, conclusions may be generalizable for other states
with low vaccine rates. The response rate was low, so bias may exist in nonresponses. Also, the
survey did not include patients or their parents, so this may not completely reflect all the views
on HPV vaccination in Utah.6
To address the barriers in rural settings mentioned in prior research, like the studies
performed by Lu et al2 and Warner et al6, Daniel et al7 enrolled a community pharmacy in the
VFC program to increase HPV vaccination. This community lacked a pediatrician and had the
lowest HPV vaccination rate in Alabama. Alabama is particularly a state of interest because it
has a below national average vaccination rate along with high rates of cancers related to HPV. 18
Pharmacies are ideal locations because most Americans live within a few miles of a community
pharmacy, they can store medication, are open longer hours, including weekends, and rural
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pharmacists are well-known, trusted community members. A major barrier Daniel et al7 wanted
to focus on was the economic factor other researchers have not especially addressed.
Most of those living in rural areas are low-income and depend on Medicaid. Children
with Medicaid can only receive vaccines from VFC providers, who provide them for free. VFC
providers in rural areas are limited or lacking, creating a barrier for most of the population that
reside in those communities. Enrolling rural pharmacies in VFC programs will improve access
and target the needs of those living there. Additionally, researchers implemented a local digital
and printed health communication campaign, which reflected local statistics. This consisted of
informational mailers, posters, pamphlets, informational materials stapled to prescription bags,
and follow-up cards for the next vaccine. The pharmacy also held a vaccine clinic prior to the
start of the school year where they had games, gave away prizes and school supplies, and
distributed HPV information.
As a result, there was a 158% increase in the number of vaccinations along with a 24%
increase in pharmacy revenue. Members of the community expressed positive feedback and
were grateful for the pharmacy’s participation in local health services, especially the vaccine
clinic. 80% of the adolescents who were vaccinated were on Medicaid. This emphasizes the
importance of having a VFC provider in rural communities due to the high ratio of low-income
families that reside there.
This study is limited due to its single community sample size. A randomized-control
study could confirm if this can be generalizable. Future studies can also include local
physicians and pediatricians, and their potential to increase HPV vaccination rates if enrolled in a
VFC program.7
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Discussion/Analysis
Based on the literature I presented, there are necessary and effective ways to increase
HPV vaccination. Since HPV is the most common STI with a last reported prevalence of 42.5
million, costing the US healthcare system $755 million in expenses, it is pertinent to address
approaches to vaccine coverage.8 Out of the more than 200 types of HPV, about 40 types can
lead to 6 different types of cancer. This includes cancer of the vagina, vulva, cervix, anus, penis,
and oropharynx.9 I believe it is especially important to educate individuals about the major link
to cancer of the oropharynx because most would not normally think this would be an association.
While HPV is common among sexually active individuals and is typically cleared by the
immune system, high-risk varieties such as 16 and 18 can persist for many years and lead to
multiple types of cancer. Risk factors include having multiple sexual partners, a sexual partner
who has had multiple sexual partners, having sex at a young age, a history of other STIs,
immunosuppression, tobacco use, OCP use, and low socioeconomic status.13 The best way to
prevent contracting HPV is through vaccination. The number of infections dropped dramatically
after the licensure of the vaccine. Since this is prophylactic, the recommended age for the first
dose of the HPV vaccine is from age 11-12 years. The first dose can begin as early as age 9
years in certain cases. Catch-up vaccines are recommended up to age 26 years. However, a
positive vaccination status does not cover all HPV types, so screening is still recommended.
Cervical cancer screening plays a huge role in detecting abnormal cervical cells and preventing
the progression of cancer.1
Lu et al2 evaluated the factors associated with HPV vaccination status in teens aged 13-17
years using the NIS-Teen from 2015-2020. They reported a 19% increase in vaccination with
males showing a larger increase than females. This may be due to catch-up reasons since the
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vaccine was not recommended for males until 2011, also leading to a narrower coverage
difference between the sexes. Notably, provider recommendations made the biggest impact on
increasing numbers versus no provider recommendation. Other factors leading to increased
vaccination included an 11 to 12-year well-child visit, age 16 to 17 years, having at least one
vaccine provider, having visits with at least 2 providers in the past year, Hispanic, non-Hispanic
Black, Alaskan Native, American Indian, and Medicaid insurance. Additionally, higher rates
were associated with a low income, living in a metropolitan area, having a single mother, and
having a mother with less education. The inequity seen in rural areas is likely due to fewer
provider recommendations because of less provider coverage and education. Even with the
substantial increase in HPV vaccination, 25% of adolescents remain unvaccinated. Provider
recommendation and patient education play the biggest role in raising vaccination numbers, in
addition to addressing demographic disparities.2
Sonawane et al3 assessed the NIS-Teen from 2015-2018 and found the biggest reason
cited by parents for vaccine refusal was safety concerns, despite decreasing AE reports. This is
due to increasing misinformation spread on the internet through social media. Again, we see the
same demographic disparity found in the study performed by Lu et al2 with most of the
unvaccinated comprising non-Hispanic Whites, higher income households, and private
insurance. The biggest exposure to false vaccine information exists in California, which boasts
the highest concern for vaccine safety. To decrease parent safety concerns, the CDC and AMA
have implemented plans to use social media to relay accurate information about the safety and
effectiveness regarding HPV vaccination.3
Sundstrom et al4 also recognized the immense negative impact of social media on the
spread of misinformation. Mothers who are anti-vaccine are the main perpetrators of the spread
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of misleading information. They also tend to be more vocal than mothers who are pro-vaccine or
neutral. To neutralize the dissemination of false information, researchers designed an online
learning platform to educate moms and create social media champions. As a result, these
mothers felt their knowledge increased and gave them the confidence to discuss the facts about
HPV throughout their social networks.4
Shay et al5 assessed the hesitancy of parents towards the HPV vaccine by recording wellchild visits where it was recommended. Most undecided parents responded with hesitancy
through a question or concern. When providers replied with patient education and answered any
questions, most parents agreed to vaccinate their children. In visits where the provider did not
engage in conversation, the parent did not agree to vaccination. Consequently, providing patient
education about HPV vaccination to hesitant parents increases the likelihood of parents agreeing
to vaccinate.5
Warner et al6 studied provider knowledge and perceived barriers to HPV vaccination.
Utah providers were surveyed because of the state’s very low rate of vaccination and previously
reported low provider knowledge. Researchers found lower knowledge in younger providers,
those not enrolled in the VFC program, and in rural areas. Low knowledge leads to low
recommendations. Targeted continuing education to these providers can increase their
knowledge about HPV vaccination. This will increase recommendations which increase parent
approval. Providers stated the barriers to vaccination were parent education and misinformation.
Health campaigns geared toward informing the public about HPV vaccination are effective ways
to educate and provide the facts.6
Daniel et al7 set out to address the low vaccination numbers in rural areas by enrolling a
rural community pharmacy in the VFC program, initiating a local health campaign, and
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organizing a back-to-school vaccine clinic. Rural community pharmacies are ideal because they
provide a solution to many access barriers. Since most of the rural population is low-income and
depends on Medicaid, adolescents on Medicaid can only receive vaccines from VFC providers.
The outcome led to an impressive increase in HPV vaccinations and positive community
feedback. Of those vaccinated, most were receiving Medicaid. Utilizing pharmacies in rural
communities and enrolling them in the VFC program can make great strides in increasing HPV
vaccination.7
Conclusion
In individuals aged 9-26, will increasing provider and parent education about the HPV
vaccine, compared to current practice, increase the rate of HPV vaccination? From the research
presented, increasing provider and parent education about the HPV vaccine will increase the rate
of vaccination, especially in areas where demographic disparities exist. Lu et al2 concluded
provider recommendation and patient education played the biggest roles in increasing HPV
vaccination. Provider education is directly related to provider recommendation and patient
education.2
Sonowane et al3 determined that parent safety concerns were at the forefront of vaccine
refusal. They revealed this was due to the considerable amount of misinformation spread
through social media. In response, organizations like the CDC have created social media health
campaigns targeted at HPV vaccine education.3 Sundstrom et al’s4 response to the negative
impact of social media on the spread of HPV misinformation led them to create social media
champions through an online learning strategy.4 This increased parent knowledge and their
confidence to educate others about the HPV vaccine. Shay et al5 assessed the hesitancy parents
verbally display during well-child visits where the HPV vaccine is recommended. They
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concluded when providers participate in education and answer any questions or concerns, parents
are agreeable to HPV vaccination. Increased provider education will increase the likelihood of
provider engagement.5
Warner et al6 found there was lower provider education about HPV in rural areas,
younger providers, and facilities not participating in the VFC program. Additionally, providers
stated parent education and misinformation were significant barriers to HPV vaccination.
Targeted continuing education for providers and public health campaigns geared toward HPV are
effective solutions.6 Daniel et al7 succeeded in addressing most of the barriers noted by Warner
et al. They enrolled a rural pharmacy in a county with very low vaccination numbers in the VFC
program and organized a local health campaign. As a result, the area saw a remarkable increase
in HPV vaccination and the pharmacy received praise from the community for its engagement in
local health initiatives.7
This research supports increasing both provider and patient knowledge about HPV to
increase vaccination. This can be done through targeted continuing education for providers,
implementing health campaigns, and increasing access to VFC providers. It is important to focus
on the socio-economic barriers that exist.2,3,4,5,6,7 Further studies should be done to address the
lower vaccination rates in non-Hispanic Whites and to assess why the disparity exists in
adolescents with mothers who have a higher education.2 Also, further research needs to be done
to measure the impact of Covid-19 and how the pandemic affected the trends of HPV vaccine
uptake due to decreased vaccine supply, resources, screening, and a strained healthcare system. 19
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